Research · Sep 3, 2026
[EWTX] Edgewise Therapeutics Thesis 2026: Clinical-Stage Cardiomyopathy-and-Muscular-Dystrophy Compounder
Edgewise Therapeutics (NASDAQ: EWTX), headquartered in Boulder, Colorado, is a Clinical-Stage-Biotech-Cardiomyopathy-and-Muscular-Dystrophy + emerging-multi-cycle-EDG-5506-and-EDG-7500-Phase-3-and-2 leader providing distinctive multi-cycle EDG-5506-Sevasemten + emerging-EDG-7500 services to substantial multi-cycle Pre-Commercial-Biotech-Clinical-Development-Patient-and-Physician-and-Health-Plan-target + multi-cycle-emerging-Becker-Muscular-Dystrophy-BMD-Patient-Population ~10,000-15,000 US-Patient + multi-cycle-emerging-Duchenne-Muscular-Dystrophy-DMD-Patient-Population ~10,000-15,000 US-Patient + multi-cycle-emerging-Hypertrophic-Cardiomyopathy-HCM-Patient-Population ~700,000+ US-Patient-and-International. The company has distinctive multi-cycle Edgewise-Therapeutics-and-Boulder-CO-and-Clinical-Stage-Biotech heritage: founded 2017 as Edgewise-Therapeutics-Kevin-Koch-Founder-and-Co-Founder; 2019-substantial-Series-B-Financing; 2020 NASDAQ Edgewise-Therapeutics-IPO ($175M proceeds); 2021-substantial-EDG-5506-Sevasemten-and-EDG-7500-Cardiomyopathy-and-Muscular-Dystrophy-Phase-2-and-Phase-3-clinical-trials; 2024-substantial-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension; 2024-substantial-EDG-5506-Sevasemten-Phase-3-and-EDG-7500-Phase-2-Cardiomyopathy-Clinical-Trial-Readouts. FY2025 closes with selected various aggregate revenue ~$0M (pre-Commercial-Biotech-Phase-3-and-Phase-2-clinical-development), adjusted EBITDA ~$-180 to -125M (Pre-Commercial-Biotech-Clinical-Development-Burn), adjusted EPS ~$-2.95 to -2.05 (pre-Commercial-Biotech-loss), net cash ~$0.55-0.75B (multi-cycle-Pre-Commercial-Biotech-Cash-Runway-into-2027), and ~62-65M shares outstanding under President & CEO Kevin Koch. The EDG-5506-Sevasemten-Muscular-Dystrophy-and-EDG-7500-Cardiomyopathy franchise deep-dive covers distinctive multi-cycle ~100-130 employees + ~Boulder-CO-HQ-Clinical-Development-Biotech-Office across US (Boulder-CO-HQ + Multi-Clinical-Trial-Site-US) + emerging multi-jurisdiction-international (Multi-Clinical-Trial-Site-Europe-and-Canada), Clinical-Stage-Biotech-Pipeline ~0% pre-Commercial-Biotech-revenue (EDG-5506-Sevasemten-Muscular-Dystrophy-Becker-and-DMD-Phase-3 + EDG-7500-Cardiomyopathy-Hypertrophic-and-Obstructive-HCM-Phase-2 + Discovery-Pipeline), 2020-NASDAQ-IPO + 2021-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Cash-Runway-Extension transformational-platform, emerging-multi-cycle Muscular-Dystrophy-Becker-and-DMD-Therapeutic-Market + emerging-Hypertrophic-Cardiomyopathy-HCM-Therapeutic-Market + emerging-Mavacamten-Bristol-Myers-Squibb-Camzyos-Approved-HCM-Reference + emerging-Aficamten-Cytokinetics-Phase-3-HCM-emerging-Approval + emerging-Sarepta-Elevidys-DMD-Gene-Therapy-Approved + emerging-Italfarmaco-Givinostat-DMD-Approved + emerging-Biotech-M&A-Activity-Large-Pharma-Acquisition structural-tailwinds, competing in Cardiomyopathy-and-Muscular-Dystrophy-Therapeutic space with Sarepta Therapeutics, Bristol-Myers Squibb/Camzyos, Cytokinetics/Aficamten, Italfarmaco/Givinostat, PTC Therapeutics, Capricor Therapeutics, Solid Biosciences, REGENXBIO, Wave Life Sciences, Stoke Therapeutics, Tenaya Therapeutics, Lexeo Therapeutics, BioMarin; Larger-Cap-Biotech-M&A-Acquirer Pfizer, Merck, AbbVie, BMY, Eli Lilly, Novartis, Sanofi, AstraZeneca; and private-equity-Biotech Flagship-Pioneering-ARCH-Third-Rock-Atlas-Polaris-Versant-OrbiMed-RA-Capital-Baker-Bros-Perceptive-Foresite-Avoro. The Kevin-Koch + Founder-CEO + multi-decade compounder thesis deep-dive covers Kevin-Koch-Founder-CEO (since 2017-Founder-CEO + Founder-Edgewise-Therapeutics-Co-Founder + Former-Array-Biopharma-and-Tecan-and-Genentech-veteran) expertise + Founder-Edgewise-Therapeutics-Co-Founder leadership-continuity, 2017-Edgewise-Therapeutics-founding + 2020-NASDAQ-IPO + 2021-EDG-5506-Sevasemten-and-EDG-7500-Phase-2-and-Phase-3-clinical-trials + 2024-Follow-On-Financing-and-Convertible-Note-and-Cash-Runway-Extension transformational-platform, no-dividend (Pre-Commercial-Biotech-Clinical-Development-Burn). Capital position is Pre-Commercial-Biotech (Not-Rated-Pre-Commercial-Biotech), Pre-Commercial-Biotech-Cash-Runway-into-2027. At ~$22-32 per share, equity value ~$1.4-2.05B, providing Pre-Commercial-Biotech-Phase-3-and-Phase-2-Clinical-Trial-Readout-Option-Value.